215 related articles for article (PubMed ID: 27228636)
1. Infections and Biological Therapy in Patients with Rheumatic Diseases.
Atzeni F; Batticciotto A; Masala IF; Talotta R; Benucci M; Sarzi-Puttini P
Isr Med Assoc J; 2016; 18(3-4):164-7. PubMed ID: 27228636
[TBL] [Abstract][Full Text] [Related]
2. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
3. [TNF inhibitors].
Kameda H
Nihon Rinsho; 2016 Jun; 74(6):957-62. PubMed ID: 27311185
[TBL] [Abstract][Full Text] [Related]
4. Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis.
Lahiri M; Dixon WG
Best Pract Res Clin Rheumatol; 2015 Apr; 29(2):290-305. PubMed ID: 26362745
[TBL] [Abstract][Full Text] [Related]
5. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
Baddley JW; Cantini F; Goletti D; Gómez-Reino JJ; Mylonakis E; San-Juan R; Fernández-Ruiz M; Torre-Cisneros J
Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S10-S20. PubMed ID: 29459143
[TBL] [Abstract][Full Text] [Related]
6. The risk of infections with biologic therapies for rheumatoid arthritis.
Furst DE
Semin Arthritis Rheum; 2010 Apr; 39(5):327-46. PubMed ID: 19117595
[TBL] [Abstract][Full Text] [Related]
7. Infection risk associated with anti-TNF-α agents: a review.
Murdaca G; Spanò F; Contatore M; Guastalla A; Penza E; Magnani O; Puppo F
Expert Opin Drug Saf; 2015 Apr; 14(4):571-82. PubMed ID: 25630559
[TBL] [Abstract][Full Text] [Related]
8. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy.
Aaltonen KJ; Joensuu JT; Virkki L; Sokka T; Aronen P; Relas H; Valleala H; Rantalaiho V; Pirilä L; Puolakka K; Uusitalo T; Blom M; Konttinen YT; Nordström D
J Rheumatol; 2015 Mar; 42(3):372-8. PubMed ID: 25593230
[TBL] [Abstract][Full Text] [Related]
9. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.
Hatzara C; Hadziyannis E; Kandili A; Koutsianas C; Makris A; Georgiopoulos G; Vassilopoulos D
Ann Rheum Dis; 2015 Oct; 74(10):1848-53. PubMed ID: 24854354
[TBL] [Abstract][Full Text] [Related]
10. Certolizumab Pegol-Induced Heart Failure.
Lazarewicz K; Shaw S; Haque S
J Clin Rheumatol; 2018 Jan; 24(1):55-56. PubMed ID: 29232326
[No Abstract] [Full Text] [Related]
11. Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis.
Johnston SS; Turpcu A; Shi N; Fowler R; Chu BC; Alexander K
Semin Arthritis Rheum; 2013 Aug; 43(1):39-47. PubMed ID: 23453683
[TBL] [Abstract][Full Text] [Related]
12. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
van Dartel SA; Fransen J; Kievit W; Flendrie M; den Broeder AA; Visser H; Hartkamp A; van de Laar MA; van Riel PL
Ann Rheum Dis; 2013 Jun; 72(6):895-900. PubMed ID: 22887849
[TBL] [Abstract][Full Text] [Related]
13. TNF-alpha antagonist induced lupus on three different agents.
Mudduluru BM; Shah S; Shamah S; Swaminath A
Postgrad Med; 2017 Mar; 129(2):304-306. PubMed ID: 27748629
[TBL] [Abstract][Full Text] [Related]
14. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
[TBL] [Abstract][Full Text] [Related]
15. Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials.
Zhang Z; Fan W; Yang G; Xu Z; Wang J; Cheng Q; Yu M
BMJ Open; 2017 Mar; 7(3):e012567. PubMed ID: 28336735
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.
Mok CC; Chan KY; Lee KL; Tam LS; Lee KW;
Int J Rheum Dis; 2014 Dec; 17 Suppl 3():1-8. PubMed ID: 24382315
[TBL] [Abstract][Full Text] [Related]
17. Paradoxical gastrointestinal reactions in patients taking tumor necrosis factor inhibitors: a rare event that broadens the histologic spectrum of medication-associated injury.
Hutchings D; Miller JA; Voltaggio L
Hum Pathol; 2019 Mar; 85():202-209. PubMed ID: 30452927
[TBL] [Abstract][Full Text] [Related]
18. Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases.
Botsios C
Autoimmun Rev; 2005 Mar; 4(3):162-70. PubMed ID: 15823502
[TBL] [Abstract][Full Text] [Related]
19. Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety.
Al-Mayouf SM; Alenazi A; AlJasser H
Int J Rheum Dis; 2016 Jun; 19(6):600-5. PubMed ID: 24730661
[TBL] [Abstract][Full Text] [Related]
20. Update upon the infection risk in patients receiving TNF alpha inhibitors.
Murdaca G; Negrini S; Pellecchio M; Greco M; Schiavi C; Giusti F; Puppo F
Expert Opin Drug Saf; 2019 Mar; 18(3):219-229. PubMed ID: 30704314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
